Company Information

  

Address: 275 MADISON AVENUE, 7TH FLOOR  
City: NEW YORK 
State: NY 
Zip Code: 10016 
Telephone: 646-677-3875 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Our most advanced products are Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications and Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML). We are currently conducting a pivotal Phase 3 trial of Iomab(TM)-B for bone marrow conditioning for HSCT in patients with relapsed or refractory AML age of 55 and older, which upon successful completion of our clinical trials we intend to submit for marketing approval. We are currently conducting a Phase 3 trial of Iomab(TM)-B for bone marrow conditioning for HSCT in patients with relapsed or refractory AML age of 55 and older, which upon successful completion of our clinical trials, we intend to submit for marketing approval. We are currently also considering filing an application with the U.S.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.52NAN/E
03/2017-0.54NAN/E
12/2016-0.50NAN/E
09/2016-0.89NAN/E
03/2016-0.91NAN/E
12/20150.55NA5.87
09/2015-0.56NAN/E
06/2015-0.68NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.16Total Liab/Total Assets0.20
Net Inc/Total Assets-1.08Total Liab/Inv Cap0.26
Net Inc/Inv Cap-1.37Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage Ratio-4856.54
Net Inc/Net SalesNACurr Debt/Equity0.02
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.02
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio4.95
Inventory TurnoverNACurrent Ratio4.95
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.81 3.28 2.90 1.39
Operating Income -7.20 -7.81 -6.83 -7.10
Interest Exp 0.00 0.00 0.00 0.00
Pretax Income -7.05 -8.06 -6.70 -6.60
Other Income 0.15 -0.26 0.13 0.50
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -7.05 -8.06 -6.70 -6.60

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 11.46 17.09 20.55 15.56
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 12.47 18.12 22.39 17.12
Net Property, Plant & Equipment 0.07 0.08 0.09 0.09
Total Assets 12.98 18.24 22.53 17.26
Liabilities        
Accounts Payable 3.68 4.79 4.22 2.60
Debt in Current Liabilities 0.43 0.58 0.30 0.43
Total Current Liabilities 4.11 5.37 4.52 3.03
Long-Term Debt NA NA NA NA
Total Liabilities 4.11 5.37 4.52 3.03
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.06 0.06 0.06 0.05
Retained Earnings -151.67 -144.61 -136.55 -129.86
Treasury Stock NA NA NA NA
Total Stockholders' Equity 8.87 12.88 18.01 14.23
Total Liabilities and Stockholders' Equity 12.98 18.24 22.53 17.26

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -7.14 -5.37 -4.24 -5.57
Net Cash Provided by Investing Activities -0.40 0.03 -0.02 -0.00
Net Cash Provided by Financing Activities 1.91 1.92 9.25 0.64

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-8.36--
12/20130.00-10.77-0.47
12/20140.00-24.69-0.90
12/20150.00-21.030.55
12/20160.00-24.32-0.50
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17304,2235.28




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.